2025
Huang X, Jannu AJ, Song Z, Jury-Garfe N, Lasagna-Reeves CA; Alzheimer's Disease Neuroimaging Initiative; Johnson TS, Huang K, Zhang J. Predicting Alzheimer's disease subtypes and understanding their molecular characteristics in living patients with transcriptomic trajectory profiling. Alzheimers Dement. 2025 Jan;21(1):e14241. doi: 10.1002/alz.14241. Epub 2025 Jan 15.
​
2024
Kim J, Tadros B, Liang YH, Kim Y, Lasagna-Reeves C, Sonn JY, Chung DC, Hyman B, Holtzman DM, Zoghbi HY.
TYK2 regulates tau levels, phosphorylation and aggregation in a tauopathy mouse model. Nat Neurosci. 2024 Dec;27(12):2417-2429. doi: 10.1038/s41593-024-01777-2. Epub 2024 Nov 11.
​
Ganegamage SK, Ademoye TA, Patel H, Alnakhala H, Tripathi A, Nguyen CCD, Pham K, Plascencia-Villa G, Zhu X, Perry G, Tian S, Dettmer U, Lasagna-Reeves C, Fortin. Evaluation of Alpha-Synuclein and Tau Antiaggregation Activity of Urea and Thiourea-Based Small Molecules for Neurodegenerative Disease Therapeutics. ACS Chem Neurosci. 2024 Nov 6;15(21):3915-3931. doi: 10.1021/acschemneuro.4c00282. Epub 2024 Oct 22.
​
Tate M, Wijeratne HRS, Kim B, Philtjens S, You Y, Lee DH, Gutierrez DA, Sharify D, Wells M, Perez-Cardelo M, Doud EH, Fernandez-Hernando C, Lasagna-Reeves C, Mosley AL, Kim J. Deletion of miR-33, a regulator of the ABCA1-APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice. Alzheimers Dement. 2024 Sep 30. doi: 10.1002/alz.14243.
​
Jury-Garfe, N., Redding-Ochoa, J., You, Y., Martinez P., Karahan H., Chimal-Juárez E., Johnson T.S., Zhang J., Resnick S., Kim J., Troncoso JC., Lasagna-Reeves CA. Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer’s disease. Acta Neuropatholica 148, 15 (2024). doi.org/10.1007/s00401-024-02775-1
Martinez P, Patel H, You Y, Doud EH, Mosley AL, Lasagna-Reeves CA. Protocol for the isolation and proteomic analysis of pathological tau-seeds. 2024; doi.org/10.1016/j.xpro.2024.103185
Codocedo JF, Mera-Reina C, Bor-Chian Lin P, Fallen PB, Puntambekar SS, Casali BT, Jury-Garfe N, Martinez P, Lasagna-Reeves CA, Landreth GE. Therapeutic targeting of immunometabolism reveals a critical reliance on hexokinase 2 dosage for microglial activation and Alzheimer's progression. Cell Rep. 2024; Jul 11;43(7):114488. doi: 10.1016/j.celrep.2024.114488.
​
​Dabin LC, Kersey H, Kim B, Acri DJ, Sharify D, Lee-Gosselin A, Lasagna-Reeves CA, Oblak AL, Lamb BT, Kim J. Loss of Inpp5d has disease-relevant and sex-specific effects on glial transcriptomes. Alzheimer's Dement. 2024; 1-13. doi: /10.1002/alz.13901​​​
​
2023
​Ramirez E, Ganegamage SK, Min S, Patel H, Ogunware A, Plascencia-Villa G, Alnakhala H, Shimanaka K, Tripathi A, Wang KW, Zhu X, Rochet JC, Kuo MH, Counts SE, Perry G, Dettmer U, Lasagna-Reeves CA, Fortin JS. Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on α-Synuclein and Tau Aggregation. ACS Chem Neurosci. 2023 Oct 11. doi: 10.1021/acschemneuro.3c00464.
Acri DJ, You Y, Tate MD, Karahan H, Martinez P, McCord B, Sharify AD, John S, Kim B, Dabin LC, Philtjens S, Wijeratne HRS, McCray TJ, Smith DC, Bissel SJ, Lamb BT, Lasagna-Reeves CA, Kim J. Network analysis identifies strain-dependent response to tau and tau seeding-associated genes. J Exp Med. 2023 Nov 6;220(11):e20230180. doi: 10.1084/jem.20230180.
​
Lee-Gosselin A, Jury-Garfe N, You Y, Dabin L, Soni D, Dutta S, Rochet JC, Kim J, Oblak AL, Lasagna-Reeves CA. TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo. Cells. 2023 Jun 10;12(12):1597. doi: 10.3390/cells12121597.
​
Moutinho M, Coronel I, Tsai AP, Di Prisco GV, Pennington T, Atwood BK, Puntambekar SS, Smith DC, Martinez P, Han S, Lee Y, Lasagna-Reeves CA, Lamb BT, Bissel SJ, Nho K, Landreth GE.TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation. Genome Med. 2023 Feb 20;15(1):11. doi: 10.1186/s13073-023-01160-z.
2022
Martinez P, Patel H, You Y, Jury N, Perkins A, Lee-Gosselin A, Taylor X, You Y, Viana Di Prisco G, Huang X, Dutta S, Wijeratne AB, Redding-Ochoa J, Shahid SS, Codocedo JF, Min S, Landreth GE, Mosley AL, Wu YC, McKinzie DL, Rochet JC, Zhang J, Atwood BK, Troncoso J, Lasagna-Reeves CA. Bassoon contributes to tau-seed propagation and neurotoxicity. Nat Neurosci. 2022 Nov 7. doi: 10.1038/s41593-022-01191-6.
​
Cisternas P, Taylor X, Martinez P, Maldonado O, Jury N, Lasagna-Reeves CA. The reduction of astrocytic tau prevents amyloid-β-induced synaptotoxicity. Brain Commun. 2022 Sep 19;4(5):fcac235. doi: 10.1093/braincomms/fcac235.
​
Puntambekar SS, Moutinho M, Lin PB, Jadhav V, Tumbleson-Brink D, Balaji A, Benito MA, Xu G, Oblak A, Lasagna-Reeves CA, Landreth GE, Lamb BT. CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer's disease. Mol Neurodegener. 2022 Jun 28;17(1):47. doi: 10.1186/s13024-022-00545-9.
​
Taylor X, Cisternas P, Jury N, Martinez P, Huang X, You Y, Redding-Ochoa J, Vidal R, Zhang J, Troncoso J, Lasagna-Reeves CA. Activated endothelial cells induce a distinct type of astrocytic reactivity. Commun Biol. 2022 Mar 29;5(1):282. doi: 10.1038/s42003-022-03237-8.
​
Moutinho M, Puntambekar SS, Tsai AP, Coronel I, Lin PB, Casali BT, Martinez P, Oblak AL, Lasagna-Reeves CA, Lamb BT, Landreth GE. The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer's disease. Sci Transl Med. 2022 Mar 23;14(637):eabl7634. doi: 10.1126/scitranslmed.abl7634.
2021
Patel H, Martinez P, Perkins A, Taylor X, Jury N, McKinzie D, Lasagna-Reeves CA. Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy. Neurobiol Aging. 2021 Sep 20;109:52-63. doi: 10.1016/j.neurobiolaging.2021.09.006.
2020
Cisternas P, Taylor X, Perkins A, Maldonado O, Allman E, Cordova R, Marambio Y, Munoz B, Pennington T, Xiang S, Zhang J, Vidal R, Atwood B, Lasagna-Reeves CA. Vascular amyloid accumulation alters the gabaergic synapse and induces hyperactivity in a model of cerebral amyloid angiopathy. Aging Cell. 2020 Sep 10:e13233. doi: 10.1111/acel.13233.
​
Taylor X, Cisternas P, You Y, You Y, Xiang S, Marambio Y, Zhang J, Vidal R, Lasagna-Reeves CA.
A1 reactive astrocytes and a loss of TREM2 are associated with an early stage of pathology in a mouse model of cerebral amyloid angiopathy. J Neuroinflammation. 2020 Jul 25;17(1):223. doi: 10.1186/s12974-020-01900-7.
2019
Cisternas P, Taylor X and Lasagna-Reeves CA. The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy. Int J Mol Sci. 2019 Dec 14;20(24).
​
You Y, Perkins A, Cisternas P, Muñoz B, Taylor X, You Y, Garringer HJ, Oblak AL, Atwood BK, Vidal R, Lasagna-Reeves CA. Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy. Acta Neuropathol Commun. 2019 Feb 26;7(1):26. doi: 10.1186/s40478-019-0680-z.
2017
Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, Kokiko-Cochran ON, Crish SD, Lasagna-Reeves CA, Ransohoff RM, Landreth GE, Lamb BT. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener. 2017 Oct 16;12(1):74.
2016
M.W. Rousseaux, M. De Haro, C.A. Lasagna-Reeves, A. De Maio, J. Park, I, Al-Ramahi, N. Lu, A. Sharma, L. Vilanova-Velez, T.F. Westbrook, J.C. Troncoso, R. Kayed, J. Botas, H.Y. Zoghbi. TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. Elife 2016 Oct 25;5.
C.A Lasagna-Reeves, M. De Haro, S. Hao, J. Park, M.W.C. Rousseaux, I. Al-Ramahi, P. Jafar-Nejad, L. Vilanova-Velez, L. See, A. De Maio, Z. Wu, J.C. Troncoso, T.F. Westbrook, J. Tang,J. Botas, H.Y. Zoghbi. Reduction of Nuak1 decreases tau and reverses symptoms in a tauopathy mouse model. Neuron 2016 Oct 19;92(2):407-418.
​
Subject of a Neuron Preview commentary by S. Maeda and L. Mucke., 2016 Oct 19;92(2):265-267.
​
Subject of a Science Signaling Editors’ Choice by Leslie K. Ferrareli., 2016 Oct 9;45: ec252. Featured at Alzforum
2015
C.A. Lasagna-Reeves, M.W.C. Rousseaux, M.J. Guerrero-Munoz, L. Vilanova-Velez, J. Park, L. See, P. Jafar-Nejad, R.Richaman, H.T. Orr, R. Kayed and H.Y. Zoghbi. ATAXIN-1 oligomers induce local spread of pathology and decreasing them by passive immunization slowls Spinocerebellar ataxia type 1 phenotypes. Elife 2015 December 17;4
​
C.A. Lasagna-Reeves, M.W.C. Rousseaux, M.J. Guerrero-Munoz, J. Park, R.Richaman, N. Lu, U. Sengupta, A. Litvinchuk, H.T. Orr, R. Kayed and H.Y. Zoghbi. A native interactor scaffolds and stabilizes toxic ATXIN-1 oligomers in SCA1. Elife. 2015 May 19;4.
Sengupta, M.J. Guerrero-Munoz, D. L. Castillo-Carranza, C.A. Lasagna-Reeves, J.E. Gerson, G.R. Jackson and R. Kayed. Synergistic toxicity of oligomeric α-synuclein and tau in synucleinopathies. Biol Psychiatry. 2015 Jan 9.
Subject of a Biological Psychiatric editorial commentary by Delenclos, M. Moussaud, S. and McLean, P.J., 2015 Nov 15;78(10):666-7.
2014
C.A. Lasagna-Reeves, D.L. Castillo-Carranza, U. Sengupta, J.E. Gerson, M.J. Guerrero-Munoz, J.C. Troncoso, G.R. Jackson and R. Kayed. The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotype. Acta Neuropathol Commun. 2014 May 29;2:56.
D.L. Castillo-Carranza, U. Sengupta, M.J. Guerrero-Munoz, C.A. Lasagna-Reeves, J.E. Gerson, G. Singh, D.M. Estes, A.D. Barrett, K.T. Dineley, J.R. Jackson and R. Kayed. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014 Mar 19;34(12):4260-72.
M.J. Guerrero-Munoz, D. L. Castillo-Carranza, S. Krishnamurthy, A. Paulucci-Holthauzen, U. Sengupta, C.A. Lasagna-Reeves, G.R. Jackson and R. Kayed. Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer’s disease. Neurobiol Dis. 2014 Nov 71:14-23.
J.E. Gerson, U. Sengupta, C.A. Lasagna-Reeves, M.J. Guerrero-Munoz, J.C. Troncoso and R. Kayed. Characterization of tau oligomeric seeds in Progressive Supranuclear Palsy. Acta Neuropathol Commun. 2014 Jun 14;2:73.
D.L. Castillo-Carranza, J.E. Gerson, U. Sengupta, M.J. Guerrero-Munoz, C.A. Lasagna-Reeves and R. Kayed. Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds. J Alzheimer’s Dis. 2014 Mar 6;40 Suppl 1: S97-S111.
2013
2012
Kayed and C.A. Lasagna-Reeves. Molecular Mechanism of Amyloid Oligomers Toxicity, J Alzheimer’s Dis. 2013 Jan 1;33(0):S67-78.
D.L. Castillo-Carranza, C.A. Lasagna-Reeves, R. Kayed. Tau aggregates as immunotherapeutic targets. Front Biosci (Schol Ed). 2013 Jan 1;5:426-38.
C.A. Lasagna-Reeves, A.L. Clos, D. Castillo-Carranza, U. Sengupta, M. Guerrero-Muñoz , B. Kelly, R. Wagner, R. Kayed. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity, Biochem Biophys Res Commun. 2013 Jan 18;430(3):963-8.
​
​
C.A. Lasagna-Reeves, D.L. Castillo-Carranza, U. Sengupta, M.J. Guerrero-Munoz, T. Kiritoshi, V. Neugebauer, G.R. Jackson, R. Kayed. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau, Sci Rep. 2012;2:700.
C.A. Lasagna-Reeves, D. L. Castillo-Carranza, U. Sengupta, J. Sarmiento, J. Troncoso, G.R. Jackson and R. Kayed. Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease, FASEB J, 2012 May;26(5):1946-59.
​
A.L. Clos, R. Kayed and C.A. Lasagna-Reeves. Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis. Front Neurol, 2012;3:5.
​
2011
2010
2009
C.A. Lasagna-Reeves and R. Kayed. Astrocytes contain amyloid-β annular protofibrils in Alzheimer’s disease brains. FEBS Lett, 2011 Oct 3;585(19):3052-7.
A.L. Clos, C.A. Lasagna-Reeves, D. L. Castillo-Carranza, U. Sengupta, G.R. Jackson, B. Kelly, Thomas M. Beachkofsky and R. Kayed. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis. Br J Dermatol, 2011 Dec;165(6):1349-54.
A.L. Clos, C.A. Lasagna-Reeves, B. Kelly, R. Wagner, M. Wilkerson, G.R. Jackson and R. Kayed. Role of oligomers in the amyloidogenesis of cutaneous amyloidosis. J Am Acad Dermatol, 011 Nov;65(5):1023-31.
C.A. Lasagna-Reeves, D. Castillo-Carranza, U. Sengupta, A.L. Clos, G.R. Jackson and R. Kayed. Tau oligomers impair memory and induce synaptic and mitocondrial dysfunction in wild type mice. Mol Neurodegener, 2011 Jun 6; 6(1):39. (Most accessed research article in the first 30 days of its publication).
C.A. Lasagna-Reeves, D. Castillo-Carranza, G.R. Jackson and R. Kayed. Tau oligomers as Potential target for immunotherapy for Alzheimer’s disease and tauopathies. Current Alzheimer Res, 2011 Sep 1;8(6):659-65.
C.A. Lasagna-Reeves, C. Glabe and R. Kayed. Amyloid- annular protofibrils evade fibrillar fate in Alzheimers disease brain. J Biol Chem, 2011 Jun 24;286(25):22122-30. (Selected as Paper of the week, top 1% of papers published in J Biol Chem).
C.A. Lasagna-Reeves, D. Castillo-Carranza, M. Guerrero-Muñoz, G.R. Jackson and R.Kayed. Preparation and Characterization of Neurotoxic Tau Oligomers. Biochemistry, 2010 Nov; 49(47):10039-10041. (Most accessed research article in the first 30 days of its publication)
C.A. Lasagna-Reeves, A.L. Clos, T. Midoro-Horiuti, R. Goldblum, G. R. Jackson and R. Kayed. Inhaled insulin forms toxic pulmonary amyloid aggregates. Endocrinology, 2010 Oct; 151(10):4717-24.
A. L. Clos, C. Lasagna-Reeves, R. Wagner, B. Kelly, G.R. Jackson and R. Kayed. Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localized intra-lesional injections of anti-amyloid antibodies. Exp. Dermatology, 2010 Oct;19(10):904-11
C. Lasagna-Reeves, D. González-Romero, M. Barria, I. Olmedo, A.L. Clos, V.M. Sadagopa Ramanujam, A. Urayama, L. Vergara, M.J. Kogan and C. Soto. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in Mice. Biochem. Biophys. Res. Commun. 2010 Mar 19; 393(4):649-55. (Top five most cited articles in BBRC since 2009).
E.W. Mina, C. Lasagna-Reeves, C.G. Glabe and R. Kayed. Polaxamer 188 copolymer membrane sealant rescues toxicity of amyloid oligomers in vitro. Journal of Molecular Biology, 2009, Aug 21; 391(3):577-85.
2008
Z. Martin-Jones and C. Lasagna-Reeves. Which is a better target for AD immunotherapy Aβ or Tau? Review. Alzheimer Dis Assoc Disord, 2008. 22 (2): 111-2.